Official Communication of the International Society for Thrombosis and Haemostasis Scientific and Standardization Committee for Lupus Anticoagulant/Antiphospholipid Antibodies

Clinical and laboratory practice for lupus anticoagulant testing: results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey

Authors:

Hannah Cohen[1,2] MBChB, MD, FRCP FRCPath, Ian J Mackie[1] PhD, FRCPath, and Katrien M. J. Devreese[3] MD PhD, on behalf of the International Society for Thrombosis and Haemostasis Scientific Standardization Committee for Lupus Anticoagulant/Antiphospholipid Antibodies

Affiliations:

[1]Haemostasis Research Unit, Department of Haematology, University College London, London, UK

[2]Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK

[3]Coagulation Laboratory, Department of Diagnostic Sciences, Ghent University Hospital, Ghent, Belgium.

Corresponding author:

Professor Hannah Cohen, Haemostasis Research Unit, Department of Haematology, University College London,1st Floor, 51 Chenies Mews, WC1E 6HX, London, UK

Tel: 0044 207 679 6419/6420

Email: hannah.cohen@ucl.ac.uk

Essentials

- Current guidelines have contributed to more uniformity in lupus anticoagulant (LA) testing

- An international survey of clinical and laboratory practice in LA testing was performed

- Some of the lack of agreement on aspects of LA testing reflects the lack of substantive data

- A more uniform approach should reduce the inter-centre variability of LA testing

Abstract

Background

Current guidelines have contributed to more uniformity in the performance and interpretation of lupus anticoagulant (LA) testing. However, points to reconsider include testing for LA in patients on anticoagulation, cut-off values and interpretation of results.

Objectives

The aim of this International Society of Thrombosis and Haemostasis Scientific Standardization committee (ISTH SSC) questionnaire was to capture the spectrum of clinical and laboratory practice in LA diagnosis, focussing on variability in practice, so that the responses could inform further ISTH SSC recommendations.

Methods

Members of the ISTH SSC on Lupus Anticoagulant/Antiphospholipid Antibodies (LA/aPL) and participants of the Lupus Anticoagulant/Antiphospholipid Antibodies Programme of the ECAT (External quality Control of diagnostic Assays and Tests) Foundation were invited to complete a questionnaire on LA testing that was placed on the ISTH website using RedCap, with data tallied using simple descriptive statistics.

Results

There was good agreement on several key recommendations in the ISTH and other guidelines on LA testing, such as sample processing, principles of testing, choice of tests, repeat testing to confirm persistent positivity and the use of interpretative reporting. However, they highlight that there is less agreement on some other aspects, including the timing of testing in relation to thrombosis or pregnancy, testing in patients on anticoagulation, cut-off values, and calculation and interpretation of results.

Conclusions

Although some of the variability in practice in LA testing reflects the lack of substantive data to underpin evidence-based recommendations, a more uniform approach, based on further guidance, should reduce the inter-centre variability of LA testing.

Introduction

Accurate diagnosis of antiphospholipid syndrome (APS) is essential to guide appropriate management with the aim of preventing the deleterious consequences of this acquired autoimmune disorder, characterised by thrombosis (arterial, venous or microvascular) and/or obstetric morbidity in association with persistently positive antiphospholipid antibodies (aPL). The laboratory diagnostic criteria for aPL positivity comprise lupus anticoagulant (LA), IgG and/or IgM anticardiolipin (aCL) and/or anti-beta 2 glycoprotein I antibodies (aβ2GPI) [1]. Identification of aPL positivity strengthens the decision for indefinite anticoagulation after a first unprovoked venous thromboembolism (VTE) or even after provoked VTE, particularly if the provoking factor for VTE appears to be disproportionately mild. It also identifies women

who require higher than standard prophylactic-dose anticoagulation with low molecular weight heparin (LMWH) during pregnancy [2-4], and who also require low-dose aspirin and monitoring for placental insufficiency [5], the latter to guide optimal timing of delivery, reducing the risk of perinatal morbidity and mortality. Approximately 50% of APS patients have LA alone [6], with LA detection therefore critical for APS diagnosis in these patients. LA is thought to carry the highest risk for thrombosis among all aPL [7] and the occurrence of a thrombotic event may be associated with higher mortality in patients with LA [8]. LA has been reported to be the primary predictor of adverse pregnancy outcome in patients with aPL associated pregnancies [9]. Detection of LA also enables diagnosis of triple-aPL positive patients, who are perceived to be the APS patients at highest risk of thrombosis [10,11], and thus, identification of LA enables risk stratification as well as appropriate management of APS patients.

External quality assessment studies on LA testing in Europe have shown considerable inter-laboratory variability, particularly in samples with "weak" LA, with false negative and false positive rates of 10-20% [12,13]. North American studies have shown false negative LA rates up to 28% and false positive rates of around 11%, while Australasian studies reported false negative rates up to 50% and false positive LA rates of about 10% [14,15]. The discrepancies appear to be due to a variety of pre- and post-analytical factors as well as performance of the tests. There are many differences between laboratories in the selection of LA tests, source of reagents, methodological detail and results [14, 15-20].

The 2009 ISTH-SSC recommendations on LA detection [21], as well as the British Committee for Standards in Haematology (BCSH) [22] and CLSI guidelines (23), have contributed to more uniformity in the performance and interpretation of LA testing. However, points to reconsider include testing for LA in patients on anticoagulation, cut-off values and interpretation of results. The aim of this ISTH SSC questionnaire was to capture the spectrum of clinical and laboratory practice in LA diagnosis, with particular focus on issues where there is variability in practice, so that the responses could help to inform the formulation of further ISTH SSC recommendations.

Methods

Survey questionnaire: A survey questionnaire (Appendix 1) on LA testing was formulated to provide a survey of respondents' views. This was placed on the ISTH website using RedCap and all members registered on the ISTH SSC on Lupus Anticoagulant/ Antiphospholipid Antibodies (SSC-aPL) website, who are workers in the field of aPL, were invited by email to participate (n=479). Additionally, participants of the "Lupus Program" external quality exercises of the ECAT Foundation (n=575) were asked to fill out the questionnaire.

Data analysis: The specific details of returned information were entered onto an Excel spreadsheet that included all records and fields, and data tallied (after the survey deadline) using simple descriptive statistics.

Results

General information

185 responses to the survey were received, the majority (58%) from laboratory scientists, with haematologists making up 22% and the remainder, other specialist clinicians, including rheumatologists. Almost three-quarters (73%) of respondents worked in a hospital laboratories, approximately 50% of whom werein University hospital laboratories. As regards the volume of samples tested, 59.1% of laboratories undertake between 500 to 4000 LA tests annually, with 5% of laboratories undertaking over 6000 and 2.8% over 10,000 LA tests annually.

Pre-analytical factors

Timing of LA testing in relation to thrombotic events: the responses to the questionnaire showed little agreement on the timing of testing in relation to a thrombotic event. The most frequent responses were to test any time after a thrombotic event (37.6%; but 79% (54 of these 68 respondents were laboratory based and probably not in a position to refuse to test),

while 33.7% stated that the timing depended on the clinical situation, with 13.8% stating that they did not know or were uncertain.

Timing of LA testing in relation to pregnancy: the questionnaire asked for views on the timing of LA testing in relation to pregnancy (excluding considerations in relation to the effect of anticoagulation on LA detection, which are covered below). The majority (60%) stated that LA testing could be done at any time in relation to pregnancy, with 20% indicating that LA testing should be deferred for at least six weeks after pregnancy. Here, 16.7% stated that they did not know or were uncertain.

Sample processing: 86.8% agreed that samples for LA should be collected and processed in line with the 2009 guidelines, i.e. blood samples, collected into 0.105 - 0.109 M sodium citrate 9:1, should be double centrifuged at 2000g for 15 min at room temperature to achieve a residual platelet count of < 10^9/L [21]; 51.1% indicated plasma for LA testing should ideally be frozen within 4 hours, although 30.8% thought that the plasma should ideally be frozen within 2 hours of collection.

Restriction of LA testing because of sample issues: 53.9% stated that they would restrict testing if the sample is haemolysed, with 29.1% and 18% stating that they would restrict LA testing if the sample is lipaemic or icteric, respectively. Of the former, 37% would reject any sample with visible haemolysis, but 33% set limits based on plasma plasma haemoglobin concentration, analyser haemolysis/icterus/lipaemia (HIL) flags or subjective scores. Some stated that they would restrict photometric based analyser testing but perform mechanical end-point clotting methods in the case of lipaemia or icterus; while 47 and 67% (for lipaemia and icterus respectively) stated that they would use analyser HIL flags or subjective scoring in decision making.

Testing for LA

Coagulation screen: 83.5% would do coagulation screening tests (prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and/or fibrinogen assay), to

provide background information about unexpected coagulopathies and undocumented anticoagulation.

LA testing: the overwhelming majority (94.5%) agreed that LA testing should include two phospholipid-dependent clotting tests, based on different principles, with LA considered positive if one of the two tests gives a positive result. The DRVVT (98.9%) and APTT using a reagent with proven LA sensitivity (79.7%) were used for LA detection by the majority of respondents.

LA mixing test and interpretation: 84.1% agreed that a mixing test should be performed, using pooled normal plasma (PNP) at a Patient:PNP ratio of 1:1. Options suggested for the ideal PNP were: a commercial PNP which has been platelet depleted at collection and is suitable for LA testing (47.5%); prepared in-house PNP (13.8%) or that either commercial or PNP are suitable (32.0%).

Confirmatory test for LA and order of testing: There were various views on when a confirmatory test for LA should be performed, with 54.9% stating that a confirmatory test should be done only when the LA screening test is prolonged; and other views that confirmatory testing should be undertaken on all samples being tested for LA (17.6%) or only when the screening and mixing tests are prolonged (25.3%) (Figure 1a). With regard to the order of testing, 69.1% agreed that the components of LA tests should be performed in a specific order, but there was less agreement as to what the order should be, with the majority (56.5%) stating the order should be Screen, Mix, Confirm and 35.5% stating that it should be Screen, Confirm, Mix (Figure 1b).

Interpretative report on LA result: there was almost universal agreement (97.3%) that an interpretative report should be provided on the LA result.

LA testing in patients on anticoagulants

LA testing in patients on Vitamin K antagonists: only 41.7% indicated that it would be appropriate to do LA testing in patients on vitamin K antagonists (VKAs), with 52.8% stating that it would not be appropriate. Among the former group, 36.5% stated that blood samples

for LA testing should be taken prior to starting the VKA, 9.5% that they would wait for at least 7 days after stopping the VKA and 50% applied other criteria (which mostly comprised: using tests unaffected by VKA; testing depending on the INR value; using a mixture of patient plasma and PNP; and one participant suggested using adapted cut-off values).

There were also various opinions about selecting samples based on the INR range, the commonest responses were that if the INR was <1.5, LA could be tested on undiluted plasma (41.9%), if the INR was 1.5-3.0, a dilute Russell's viper venom time (DRVVT) (34.3%) or silica clotting time/APTT (16.9%) could be used on a 1:1 patient:PNP mixture. Some respondents (13.4%) would test on equal volume mixtures of plasma regardless of INR up to an INR of 8.0 (Figure 2a). Alternative tests such as Taipan/Ecarin Venom time (TVT/ECT) are not commonly used (7%).

LA testing in patients on low molecular weight heparin (LMWH) or unfractionated heparin (UFH): there were a variety of opinions about whether and when to test in such patients: not to test patients on LMWH/UFH (33.5%); test for LA during the trough period (i.e. at least 18 hours after the last dose) on therapeutic LMWH (32.4%) or prophylactic LMWH (27.5%); or to test on prophylactic, but not therapeutic LMWH or UFH (25.8%). Approximately 10% did not know or were uncertain as to whether or when to test for LA in individuals on LMWH or UFH.

There were also differences in opinion about verification of the plasma heparin level in relation to the dose, to ensure that the LA method is unaffected by anticoagulation: 42.2% stated that an anti-Xa assay should be performed for LMWH regardless of whether the patient received therapeutic or prophylactic dose, whereas only 15.7% would test for therapeutic dosing only. There was less confidence about dealing with UFH: 21.1% would perform APTT or anti-Xa assay regardless of type of dose and 10.2% would test for therapeutic dosed patients only; 33% stated that they did not know or were uncertain about the appropriate action in patients receiving LMWH or UFH (Figure 2b).

LA testing in patients on direct oral anticoagulants (DOACs): 70.3% stated that LA testing should not be undertaken in patients on DOACs. There were various suggestions about pre-

analytical strategies such as testing during the trough period (17%) or after pre-treatment of the sample with commercial adsorbant or antidote preparations (11%). A small proportion (2.7%) stated that LA testing may be undertaken in some circumstances in patients on DOACs during the peak period.

There were also various suggestions about which tests to do, both for factor Xa (FXa) inhibitors and dabigatran. For patients receiving FXa inhibitors, 35% would use the DRVVT during the trough period and undertake a specific DOAC assay. However, almost half the respondents (49.4%) stated they did not know or were uncertain about how to test for LA in patients on DOACs (Figure 2c).

Cut-off values and calculations for LA tests

Plasma for normalisation of clotting times: there was little agreement on the ideal plasma for the calculation of normalised ratios, as shown in Figure 3a.

Number of healthy adult donors for the preparation of in-house pooled PNP used for the calculation of normalised ratios: 29.7% stated that at least 6 healthy adult donors should be used, whereas 55.7% stated that the number of donors should be at least 40 and 14.6%, that a larger number of donors should be used (Figure 3b).

Derivation of normalisation of clotting times: 65.7% of respondents stated that the denominator to derive normalisation of clotting times should be PNP analysed in the same run and 19.4% that the denominator should be the mean of the reference interval; 11.4% stated that they did not know or were uncertain.

Cut-offs for screen, mixing and confirmatory tests based on testing on plasmas from healthy donors: 50% stated that the cut-off should be the value above the 99th centile of the distribution, 33.9% the value above the 97.5th centile and 10.6% did not know or were uncertain (Figure 4a).

In-house cut-off values were calculated by 78.9% of respondents' laboratories. Over half (58.1%) stated that cut-off values could be based on 60-120 healthy donors, with the remainder of views on the number of donors for cut-off values ranging between < 20 and

120, with 14.0% stating that they did not know or were uncertain (Figure 4b). Among those who indicated to use the 99th centile only 12% indicated to use > 120 healthy donors to do so, 13% indicated to use 60-120 healthy volunteers, the majority (56%) indicated to use 20-60 healthy donors. Reasons given to not calculate in-house cut-off values were that it is too laborious, the high cost and no availability of healthy donors.

Confirmation of manufacturer cut-off values for LA positivity by local validation: 81.2% agreed that this should be undertaken, whereas 8.8% did not agree and 9.9% did not know or were uncertain.

Cut-off for the percentage correction (if used) based on testing on plasma from healthy donors mixed with the PNP at 1:1 proportion: there were divided views as to whether the percentage correction should be above the 99th or 97.5[th] centile, with 39.5% stating that this should be the value above the 99th centile of the distribution, 31.4 above the 97.5[th] centile and 24.4 % stating that they did not know or were uncertain (Figure 5a).

Interpretation of the mixing test: approximately half the respondents (45.8%) used a normalised clotting time, with 17.5% using the Rosner index (index of circulating anticoagulant), both Rosner index and normalized clotting time (15.3%) and 12.4% stating that they did not know or were uncertain (Figure 5b).

Confirmation of persistent LA positivity: 88.8% stated that a first LA should be confirmed to be persistently positive on a second sample after 12 weeks.

Discussion

The results of this ISTH SSC survey are encouraging as they show good agreement on several key recommendations in the current ISTH and other guidelines on LA testing [21-23], such as sample processing, principles of testing, choice of tests, repeat testing to confirm persistent positivity and the use of interpretative reporting. However, they highlight that there is less agreement on some other aspects of LA testing, including the timing of testing in relation to thrombosis or pregnancy, testing in patients on anticoagulation, cut-off values, and calculation and interpretation of results. Although some of the variability in

practice reflects the lack of substantive data to underpin evidence-based recommendations, a more uniform approach in many aspects of LA testing should be feasible and would reduce the inter-centre variability in LA test results.

Notably, the responses to the survey showed little agreement on the timing of testing in relation to a thrombotic event. The 2009 ISTH guideline advises caution in interpretation of LA results close to a thromboembolic event, as patients may be treated with full doses of heparin and/or VKA and furthermore, acute-phase reactants such as FVIII may be increased during acute events [21]. aPL may fluctuate and be downregulated during pregnancy, and LA tests may not be representative during all three trimesters [24-26]. LA testing may be required during pregnancy, particularly when patients with pregnancy morbidity have not been previously investigated for aPL. In this situation, LA testing should be undertaken with the cognisance that negative aPL during pregnancy does not exclude a diagnosis of APS and that testing should be undertaken post-delivery to establish true aPL status.

The rejection of samples due to haemolysis appeared to be common, but lower numbers of respondents rejected samples because of lipaemia or icterus. Local policies are likely to vary depending on the type of analyser used, its end-point detection system and the ability to objectively assess the level of the interfering substance.

There is not uniform agreement on LA testing in patients on anticoagulation with regard to whether to test or not and which methods to use, and this is reflected in the variable approaches suggested by respondents to the survey. Only 42% indicated that it would be appropriate to do LA testing in patients on VKAs, with various opinions on criteria for timing of blood sampling. Opinion was also varied about testing at different INR ranges, whether one should do the test on mixed plasmas and which tests to do. While LA testing in patients on VKA is challenging, definition of LA status in patients on VKA could identify APS patients with single aPL positivity for LA. The TVT/ECT test for LA may be useful in patients on VKA as, unlike Russell Viper venom, Taipan venom directly activates prothrombin and is not affected by VKA [27-29]. The TVT/ECT test is currently being validated in an ISTH SSC project in APS patients on VKAs [30], but appears to have good specificity, although (in non-

anticoagulated patients) it is less sensitive than the DRVVT [31]. In APS patients on DOAC FXa inhibitors, APTT-based tests are problematic and false positive results have been reported with the DRVVT, even at trough rivaroxaban levels [32]. The TVT/ECT has been shown to be unaffected by rivaroxaban [33,34]. The use of adsorbent reagents to remove DOAC and allow LA testing in the normal way are being explored and preliminary results are encouraging [35-37].

There were various views on when a confirmatory test for LA should be performed, with 55% of respondents stating that confirmatory testing should only be undertaken when the screening test is prolonged. The majority of respondents (69%) agreed that the components of lupus anticoagulant tests should be performed in a specific order, but there was less agreement as to what the order should be. The range of views probably reflects the variability between individual laboratories with regard to how they are set up in terms of analysers, degree of automation, computer systems and logistics and these factors should be taken into account when making recommendations on LA testing.

There was considerable lack of agreement on the majority of aspects related to cut-off values and calculation and interpretation of results. While 79% stated that they calculate their own in-house values, there were divided views on whether the cut-off should be the 99th or the 97.5[th] centile. It is important that any recommendation about this should have a valid statistical basis [38]. Laboratories need to consider whether they are calculating an in-house cut-off value (in which case at least 120 different healthy normal subjects are needed to calculate the 97.5[th] percentile with 95% confidence) or verifying a manufacturer's cut-off (when 20-40 normal subjects may be used) [39-41]. The minimum sample size for a reliable estimation of the 99th percentile is at least 300 [42]. The poor agreement on the number of donors needed to calculate the cut-off is probably determined by the local availability and costs rather than strong views about what should be done.

In conclusion, the good agreement on several key recommendations in the current ISTH and other guidelines on LA testing [21-23], such as sample processing, principles of testing, choice of tests, repeat testing to confirm persistent positivity and the use of interpretative

reporting, suggests that that the recommendations on LA testing are associated with more uniformity in LA testing between different laboratories. The lack of agreement on other aspects of LA testing, including the timing of testing in relation to thrombosis or pregnancy, testing in patients on anticoagulation, cut-off values, and calculation and interpretation of results, at least in part, reflects the lack of substantive data to underpin evidence-based recommendations. However, a more uniform approach in these aspects of LA testing, based on further guidance that addresses these areas, should reduce the inter-centre variability of LA testing.

Addendum

Hannah Cohen devised and analysed the survey questionnaire, wrote the first draft of the manuscript and undertook critical revision of the manuscript. Katrien Devreese devised the questionnaire and undertook critical revision of the manuscript. Ian Mackie provided critical review of the LA survey questionnaire and undertook critical revision of the manuscript.

Conflict of Interest

Hannah Cohen, Ian Mackie and Katrien Devreese have no relevant conflicts of interest to declare.

Reference list

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006; **4**: 295-306.
2. Royal College of Obstetricians and Gynaecologists guidelines: reducing the risk of venous thromboembolism during pregnancy and puerperium. *Green-top guideline* No. 37a. 2015.
   https://www.rcog. org.uk/en/guidelines-research-services/guidelines/gtg37a/.
3. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**: e691S–736S.
4. Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes- Matthes B, Schinzel H, Spannagl M, Thaler CJ. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. *Thromb Haemost* 2007; **98**: 1237–45.
5. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF, Khamashta M, King J, Lojacono A, Marchiori F, Meroni PL, Mosca M, Motta M, Ostensen M, Pamfil C, Raio L, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; **76**: 476–85.
6. Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. *Lupus* 2013; **22**: 18-25.
7. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. *Blood* 2003; **101**: 1827-1832.
8. Gebhart J, Posch F, Koder S, et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). *Blood* 2015; **125**: 3477-3483.
9. Lockshin MD, Kim M, Laskin CA, Guerra M, Ware Branch D, Merrill J, Petri M, Porter F, Sammaritano L, Stephenson MD, Buyon J, Salmon JE. Lupus anticoagulant, but not anticardiolipoin antibody, predicts adverse pregnancy outcome in patients with antiphospholipid antibodies. *Arthritis Rheum* 2012; **64**: 2311–2318.
10. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Paday- attil JS, Iliceto S. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. *J Thromb Haemost* 2010; **8**: 237–42.
11. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, De Micheli V, Gresele P, Tonello M, Ghirarduzzi A, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. *Blood* 2011; **118**: 4714-8.
12. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. *Thromb Haemost* 1997; **77**: 934-7.
13. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. *Br J Haematol* 2002; **119**: 364-9.

14. Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by North American clinical laboratories. *Am J Clin Pathol* 2010; **134**: 764-73.
15. Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II-Lupus anticoagulant. *Semin Thromb Hemost* 2012; **38**: 404-11.
16. Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. *Clin Chem* 2007; **53**: 1629-35.
17. Adams M. Measurement of lupus anticoagulants: an update on quality in laboratory testing. *Semin Thromb Hemost* 2013; **39**: 267-71.
18. Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. *Eur J Haematol* 2009; **83**: 1-16.
19. Moffat KA, Ledford-Kraemer MR, Plumhoff EA, McKay H, Nichols WL, Meijer P, Hayward CP. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. *Thromb Haemost* 2009; **101**: 178-84.
20. Devreese KM. Antiphospholipid antibody testing and standardization. *Int J Lab Hematol* 2014; **36:** 352-63.
21. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, DE Groot PG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost* 2009; **7**: 1737-40.
22. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. *Br J Haematol* 2012; **157**: 47-58.
23. CLSI Guideline. Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A, 2014. 2014. *Clinical and Laboratory Standards Institute*, Wayne, PA, USA.
24. Topping J, Quenby S, Farquharson R, Malia R, Greaves M. Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome. *Hum Reprod* 1999; **14**: 224-8.
25. Donohoe S, Quenby S, Mackie I, Panal G, Farquharson R, Malia R, Kingdom J, Machin S. Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal and heparin-treated antiphospholipid syndrome pregnancies. *Lupus* 2002 ; **11**: 11-20.
26. Kwak JY, Barini R, Gilman-Sachs A, Beaman KD, Beer AE. Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome. Am J Obstet 1994; **171**:239-46.
27. Rooney AM, McNally T, Mackie IJ, Machin SJ. The Taipan snake venom time: a new test for lupus anticoagulant. *J Clin Pathol* 1994; **47**: 497-501.
28. Parmar K, Lefkou E, Doughty H, Connor P, Hunt BJ. The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. *Blood Coagul Fibrinolysis* 2009; **20**: 271-5.
29. Moore GW, Smith MP, Savidge GF. The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants. *Blood Coagul Fibrinolysis* 2003; **14**: 307-12.
30. Moore GW. An international, multi-centre study to validate the Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as confirmatory test Subcommittee: Lupus anticoagulant/antiphospholipid antibodies, https://www.isth.org/members/group.aspx?id=100353
31. Moore GW, Culhane AP, Maloney JC, Archer RA, Breen KA, Hunt BJ. Taipan snake venom time coupled with ecarin time enhances lupus anticoagulant detection in nonanticoagulated patients. *Blood Coagul Fib* 2016; 27: 477-480.

32. Martinuzzo ME, Forastiero R, Duboscq C, Barrera LH, Lopez MS, Ceresetto J, Penchasky D, Oyhamburu J. False-positive lupus anticoagulant results by DRVVT in the presence of rivaroxaban even at low plasma concentrations. *Int J Lab Hematol 2018;* **40***: e99-e101.*

33. Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. *Thromb Res* 2015; **135**: 388-93.

34. van Os GM, de LB, Kamphuisen PW, Meijers JC, de Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. *J Thromb Haemost* 2011; **9**: 1657-9.

35. Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple method for removing DOACs from plasma samples. *Thromb Res* 2018; **163**:117-122.

36. Favresse J, Lardinois B, Sabor L, Devalet B, Vandepapeliere J, Braibant M, Lessire S, Chatelain B, Jacqmin H, Douxfils J, Mullier F. Evaluation of the DOAC-Stop procedure to overcome the effect of DOACs on several thrombophilia screening tests. *TH Open* 2018; **2**: e202-e209.

37. Platton S, Hunt C. Influence of DAOC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban. *Int J Lab Haematol* 2019; **41**: 227-233.

38. Vanoverschelde LAB, Kelchtermans H, Musial J, de Laat B, Devreese KMJ. Influence of different Anticardiolipin and Anti-β2 Glycoprotein I Antibody Cut-off Values on Antiphospholipid Syndrome Classification. *Research and Practice in Thrombosis and Haemostasis* 2019. Accepted for publication.

39. CLSI. EP28-A3C Defining, establishing and verifying reference intervals in the clinical laboratory: Approved guideline, 3rd Ed. Wayne, PA; CLSI 2008; **28**: 1-76.

40. Castellone DD. Establishing reference intervals in the coagulation laboratory. *Int J Lab Hem* 2017; **39** (Suppl 1): 121-7.

41. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL, Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. *J Thromb Haemost* 2014; **12**: 792-5.

42. Hickman PE, Badrick T, Wilson SR, McGill D. Reporting of cardiac troponin - problems with the 99th population percentile. *Clinica Chimica Acta; International Journal of Clinical Chemistry* 2007; **381**: 182-3.

Legends to Figures

Figure 1. Responses to questions about performance of LA tests
a) When should a confirmatory test for LA be performed? (182 respondents)
b) If you think that it is important to perform the components of the LA test in a specific order, what should it be? (124 respondents)

Figure 2. Responses to questions about performance of LA tests in patients on anticoagulants
a) If doing LA tests in patients on VKAs (218 respondents)
b) If doing LA tests in patients on LMWH or UFH (202 respondents)
c) If doing tests in patients on DOACs (180 respondents)

Figure 3. Responses to questions about normalised ratios
a) Which type of plasma should be used for normalisation? (191 respondents)
b) If in-house PNP is used for normalisation, how many donors should be used for the pool (158 respondents)

Figure 4. Responses to questions about cut-off values
a) What should the values be for screen, mixing and confirmation tests, derived from tests on plasmas from healthy donors? (180 respondents)

b) In–house cut-off values (percentiles) should be calculated using how many healthy donor plasmas) (179 respondents)

Figure 5. Responses to questions about percentage correction and interpretation
a) What should be the cut-off for percentage correction, when testing plasmas from healthy donors mixed 1:1 with PNP? (172 respondents)
b) How do you interpret the mixing test? (177 respondents)

Figure 1

a

2%

25%

55%

18%

- ■ Only when screening test prolonged
- ■ On all samples tested for LAC
- ■ Only when screening and mixing tests prolonged
- ■ Don't know or uncertain

b

5%

3%

56.5%

35.5%

- ■ Screen, Mix, Confirm
- ■ Screen, Confirm, Mix
- ■ All 3 run at the same time
- ■ Don't know or uncertain

18

Figure 2

a

■ (blue)	INR <1.5, test on undiluted plasma
■ (red)	INR 1.5-<3.0, 1:1 patient:PNP-DRVVT
■ (green)	INR 1.5-<3.0, 1:1 patient:PNP-SCT/aPTT
■ (purple)	1:1 patient:PNP unless INR >8.0
■ (orange)	DRVVT 1:1 patient:PNP + TSVT/ECT ratio
■ (black)	Different criteria to those above
■ (brown)	Don't know or uncertain

b

■ (blue)	Anti-Xa for LMWH-therapeutic dose
■ (red)	Anti-Xa for LMWH-therapeutic or prophylactic dose
■ (green)	APTTr or anti-Xa for UFH-therapeutic dose
■ (purple)	APTTr or anti-Xa for UFH-therapeutic or prophylactic dose
■ (orange)	Don't know or uncertain

19

C

- **FXa inhibitors: test in trough by DRVVT & specific DOAC assay** (blue)
- **TVT/ECT suitable for Xa inhibitors** (red)
- **State test you would do for dabigatran** (green)
- **Don't know or uncertain** (purple)

31%
8%
18%
43%

Figure 3

a

9 %

6 %

38 %

32 %

15 %

- ■ Commercial PNP
- ■ In-house PNP
- ■ Either commercial or in-house PNP
- ■ Commercial LAC -ve control plasma
- ■ Don't know or uncertain

15 %

b

30 %

56 %

- ■ ≥ 6 healthy adult donors
- ■ ≥ 40 healthy adult donors
- ■ A larger number of adult donors

21

Figure 4

a

- ■ Value above 99th centile
- ■ Value above 97.5th centile
- ■ Other
- ■ Don't know or uncertain

b

- ■ <20 donors
- ■ 20-60 donors
- ■ Other
- ■ Don't know or uncertain
- ■ 60-120 donors
- ■ >120 donors

Figure 5

a

24%   40%

5%

31%

- ■ Value above 99th centile
- ■ Value above 97.5th centile
- ■ Other
- ■ Don't know or uncertain

b

12%   18%

9%

15%

46%

- ■ Rosner index
- ■ Normalized clotting time
- ■ Rosner index and normalized clotting time
- ■ Other
- ■ Don't know or uncertain